Align Technology, Inc.
ALGNHIGH VELOCITYFILING INTENSITYAlign Technology, Inc. reads as an High Velocity (composite 70/100); Consistent Strategic Buyer deploying $167M across 2 disclosed transactions, down 62% vs the prior cycle · primary market Life Sciences.
Lens
Disclosed M&A capital (2023–2025)
$167M
vs $441M in 2020–2022
Disclosed transactions
2
3/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
70
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $814M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 34d
- 286 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 4 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 4 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 4 activism filings
- Latest activism 13y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 4 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 286 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $11.1B
- 10-Q 34d ago
- 2 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $421M · Peak count: 1
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 1 | $77M | $77M | N/A |
| 2024 | 1 | $77M | $77M | N/A |
| 2023 | N/A | $12M | N/A | N/A |
| 2022 | N/A | $12M | N/A | N/A |
| 2021 | N/A | $8M | N/A | N/A |
| 2020 | 1 | $421M | $421M | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Technology Acquisition20%
- Platform20%
- Geographic Expansion20%
- Bolt On20%
- Talent Acquisition20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- technology_acquisition
- platform
- geographic_expansion
- bolt_on
- talent_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“actions by us or our competitors such as price reductions, aggressive product promotions, changes in or the launch or termination of products or product lines, and mergers, consolidations and liquidations;”
“We believe the acquisition of Cubicure will support our long-term growth strategy by enabling us to scale our 3D printing operations to eventually direct print millions of custom appliances per day.”
“The Cubicure Acquisition is intended to support and scale our strategic innovation roadmap and strengthen the Align Digital Platform.”
“We acquired Cadent Holdings, Inc. in April 2011 for their people, their technology and their existing revenue streams”
“We completed the acquisition of our Asia Pacific distributor on April 30, 2013.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
ALGN trades at a -2.3-turn discount to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 2.7×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
Align Technology, Inc.ALGN | 13.8× | 2.7× | N/A | $4.1B | $167M |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)272026-02-27
- 10-Q (quarterly)782026-05-06
- 8-K (event)2862026-05-01
- Proxy / DEF 14A402026-04-17
- Activism (13D / DFAN / PREC)42013-11-14
Signals on file
- elevated
Activism on file
2013-11-144 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.